Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2007
06/07/2007WO2006126939A8 Novel 8-sulfonylamino-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor
06/07/2007WO2006116532A3 Synthesis of oligo/poly(catechins) and methods of use
06/07/2007WO2006113495A3 Dicarboxylic acid ester derivatives of ginsenoside, pharmaceutical preparations containing the same, and preparation thereof
06/07/2007WO2006106103A3 Prevention of hiv- infection with tmc278
06/07/2007WO2006102410A3 Minimally invasive clinical treatment method for closure of umbilical hernias
06/07/2007WO2006101867A3 Treatment of inflammatory bowel disease
06/07/2007WO2006097809B1 Novel tyrosine derivatives
06/07/2007WO2006096404A3 Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues
06/07/2007WO2006084882A8 Substituted 4-(indol-3-yl)quinazolines and their use
06/07/2007WO2006084116A3 Amine derivative containing compositions and methods for the treatment of viral infections related to the etiology of cancer
06/07/2007WO2006081331A3 Quinoxaline derivatives as antitumor agents
06/07/2007WO2006074147A3 Nitrogen containing bicyclic compounds and therapeutical use thereof
06/07/2007WO2006074127A3 Biomarkers for identifying efficacy of tegaserod in patients with chronic constipation
06/07/2007WO2006071459A3 System and method for power management in mobile units
06/07/2007WO2006062898A3 Compounds and methods for treating hemorrhagic fever viruses
06/07/2007WO2006060736A3 A composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
06/07/2007WO2006051413A8 Azabenoxazoles for the treatment of cns disorders
06/07/2007WO2006049564A8 New modified release pellet formulations for proton pump inhibitors
06/07/2007WO2006046031A8 Pharmaceutical compounds
06/07/2007WO2006042100A3 Method for the treatment of polycystic kidney disease
06/07/2007WO2006024640A3 Triazolophthalazines
06/07/2007WO2005110418A3 Transdermal administration of phycotoxins
06/07/2007WO2005074658A3 Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia
06/07/2007WO2005065660A3 Ziprasidone formulations
06/07/2007WO2005042584A3 Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
06/07/2007WO2005037071A3 Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
06/07/2007WO2005016234A3 Compositions, methods, apparatuses, and systems for singlet oxygen delivery
06/07/2007WO2004087873A3 Methods of treating xerostomia and xerophthalmia
06/07/2007WO2000027375A3 Idarubicin plus melphalan conditioning regimen
06/07/2007US20070129558 Monohalogenovinyl vitamin d derivative compounds
06/07/2007US20070129550 Amino acids with affinity for the alpha-2-delta-protein
06/07/2007US20070129549 Stable lamotrigine pharmaceutical compositions and processes for their preparation
06/07/2007US20070129548 Physiochemical properties; stability; medicinal properties; and good processing properties; osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism
06/07/2007US20070129547 Process to prepare substituted imidazopyrazine compounds
06/07/2007US20070129544 Novel heteroaryl substituted piperidine derivatives which are L-CPT1 inhibitors
06/07/2007US20070129448 Compositions and methods of delivery of pharmacological agents
06/07/2007US20070129447 Method of drug therapy in treatment of cardiac arrhythmias
06/07/2007US20070129446 Use of fepradinol for the production of a pharmaceutical composition for the treatment of rosacea
06/07/2007US20070129445 Therapeutic Agents
06/07/2007US20070129444 Novel weight reduction composition and uses thereof
06/07/2007US20070129443 Production method of aminochlorohydrin sulfate
06/07/2007US20070129441 Protection of cells from adverse external or intrinsic effects, cellular degeneration and death by n-acylethanolamines
06/07/2007US20070129440 Polypharmacophoric agents
06/07/2007US20070129439 Compositions containing substituted quinolines and substituted diphenyl sulfones and methods of use
06/07/2007US20070129438 Method for suppressing proliferation of abnormal prion protein
06/07/2007US20070129437 Process for preparing simvastatin and intermediates thereof
06/07/2007US20070129436 Agent for Suppressing Body Fat Accumulation
06/07/2007US20070129435 Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence
06/07/2007US20070129434 Analgesics and methods of use
06/07/2007US20070129433 Diphenylamine derivatives
06/07/2007US20070129432 Zinc-monocysteine complex and method of using zinc-cysteine complexes
06/07/2007US20070129431 For therapy of cellular proliferative diseases
06/07/2007US20070129430 Agent for enhancing the production of collagen, their preparation and use
06/07/2007US20070129429 warfarin analogs with side effect reduction
06/07/2007US20070129428 Composition for improving skin, hair and coat health containing flavanones
06/07/2007US20070129427 Novel compound and pharmaceutical composition
06/07/2007US20070129426 Therapeutic drugs for arthritis
06/07/2007US20070129425 Biocompatibility lipid solubilizer containing bile acid; bioavailability
06/07/2007US20070129424 Method for treating pain
06/07/2007US20070129423 Method for treating pain
06/07/2007US20070129422 Somatostatin receptor 1 and/or 4 selective agonists and antagonists
06/07/2007US20070129421 Such as 3-[(5-Fluoro-3-methyl-1H-indol-2-yl)-phenyl-methyl]-4-hydroxy-5-isopropyl-1,5-dihydro-pyrrol-2-one which inhibits chymase
06/07/2007US20070129420 New pyrrolidinium derivatives
06/07/2007US20070129419 Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
06/07/2007US20070129418 di-tert-butyl 4-{[1-(3,3-dimethyl-2-oxobutyl)-6-methoxy-1-H-indazole-3-yl]carbonyl}benzylphosphate; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, elevated intraoccular pressure in the eye
06/07/2007US20070129417 cannabinoid receptor modulators such as 1-cyclohexyl-4,5,6,7,8,9-hexahydro-1H-cyclooctapyrazole-3-carboxylic acid (adamantan-1-ylmethyl)-amide, used as dietetics, neuroprotectants, cognition activators, for treating diabetes, vision defects, psychological, respiratory system or gastrointestinal disorders
06/07/2007US20070129416 4,4,5,5, Tetrasubstituted imidazolines
06/07/2007US20070129415 Method of Treating Isolated Systolic Hypertension
06/07/2007US20070129414 Reacting1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one, 2-methyl imidazole the presence of an acid, an alkylsilylhalide compound or an acylhalide compound, in a solvent; used as an anti-vomiting agent
06/07/2007US20070129413 Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives
06/07/2007US20070129412 Methods for treating parkinson's disease
06/07/2007US20070129411 Treatment of proliferative diseases with epothilone derivatives and radiation
06/07/2007US20070129410 Octahydrophenanthrene hydrazinde derivatives useful as glucocorticoid receptor modulators
06/07/2007US20070129409 Androgen receptor modulators
06/07/2007US20070129408 New compounds for the treatment of neurological, psychiatric or pain disorders
06/07/2007US20070129407 Anthranilamides, process for the production thereof, and pest controllers containing the same
06/07/2007US20070129406 Novel substituted sulfoxides
06/07/2007US20070129405 Novel process for preparation of substituted sulfoxides
06/07/2007US20070129404 kinase enzyme inhibitor 5-[4-(1-amino-1-methylethyl)phenyl]-1H-indazole, useful as a drug treating eye diseases including glaucoma
06/07/2007US20070129403 Method of treating schizophrenia and/or glucoregulatory abnormalities
06/07/2007US20070129402 Donepezil; pharmacokinetics; single-dose administration of the formulation to a patient provides a blood plasma level profile with a dosage-corrected Cmax
06/07/2007US20070129401 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
06/07/2007US20070129400 Modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity, and use thereof
06/07/2007US20070129399 Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors
06/07/2007US20070129398 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis
06/07/2007US20070129397 Ester derivatives
06/07/2007US20070129396 Muscarinic acetylcholine receptor antagonists
06/07/2007US20070129395 pure crystalline form of Temsirolimus (CCI-779)
06/07/2007US20070129394 Rapamycin conjugated to peptides of up to 10 amino acid units through a carbamate linkage at position 42; coated stents; restenosis, cancer, autoimmune, transplant rejection
06/07/2007US20070129393 1-(5-Chloro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)-3-(2-methoxyphenoxy)propan-2-ol hydrochloride; modulators of chemokine receptor; autoinuune, inflammatory, porliferative diseases; antagonists
06/07/2007US20070129392 Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
06/07/2007US20070129391 Composition for preventing or treating damages of the mucosa in the gastrointestinal tracts
06/07/2007US20070129390 Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
06/07/2007US20070129389 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide; for neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma
06/07/2007US20070129388 Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid
06/07/2007US20070129387 Maleate salts of a quinazoline derivative useful as an antiangiogenic agent
06/07/2007US20070129386 Multiple sclerosis; hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, or diabetes; can be used in combination with an anti-hemorrhagic viral infection agent, immunosuppressant
06/07/2007US20070129385 Amorphous valganciclovir hydrochloride
06/07/2007US20070129383 Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof
06/07/2007US20070129382 Crf receptor antagonists, their preparations, their pharmaceutical composition, and their uses